Effect of Aspirin at the Acute Phase of Cerebral Ischemic Event.
Information source: Central Hospital, Nancy, France
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ischemic Stroke
Intervention: Aspirin (Drug); blood sample (Biological)
Phase: N/A
Status: Recruiting
Sponsored by: Central Hospital, Nancy, France Overall contact:
Sébastien Richard, MD, Phone: 3 83 85 16 56, Ext: 0 33, Email: s.richard@chu-nancy.fr
Summary
Aspirin is the only anti-platelet medication used at the acute phase of ischemic stroke. The
investigators would like to study laboratory effect of the first oral 300 mg dose of
aspirin, given at hospital, after an ischemic event.
The principal hypothesis is that platelet activity would be able to recover during this day
and could lead to ischemic recurrences.
Two blood samples are accomplished. The first 2 hours after aspirin intake and the second 23
hours after. Photometric aggregometry are performed with arachidonic acid and collagen
induced platelet aggregation, measure of thromboxan B2 levels and reticular platelets count.
Clinical Details
Official title: Laboratory Effect on Platelet Activity of the First 300 mg Oral Dose Aspirin at the Acute Phase of Cerebral Ischemic Event.
Study design: Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Measure of platelet activity recovery within 24 hours after the first 300 mg oral dose of aspirin given at hospital at the acute phase of ischemic stroke
Secondary outcome: Measure of effect of the first 300 mg oral dose of aspirin given at the acute phase of cerebral ischemic stroke for already aspirin treated
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult men and women
- Ischemic stroke less than 48 hours
- Signed consent
Exclusion Criteria:
- Danger to prescription of aspirin (haemorrhagic risk...)
- Prescription of heparin or VKA
Locations and Contacts
Sébastien Richard, MD, Phone: 3 83 85 16 56, Ext: 0 33, Email: s.richard@chu-nancy.fr
Hopital central, Nancy 54035, France; Recruiting
Sébastien Richard, MD, Phone: 3 83 85 16 56, Ext: 33 0, Email: s.richard@chu-nancy.fr
Sébastien Richard, MD, Principal Investigator
Additional Information
Starting date: December 2010
Last updated: June 20, 2011
|
